As an innovator in the medical field, Ke Ranhong was awarded "20 18 Industry Innovation Leader of the Year in China" by the media because he founded "Medical Enjoy Marketing". In the same year, this profession almost put her in jail.
The full name of medical sharing sales is Hangzhou Medical Sharing Sales Health Management Co., Ltd., which has launched a two-way cross-border medical technical service platform to "provide overseas medical service consultation" for customers and help patients find medical treatment from hospitals and medical experts around the world. Simply put, it is to help domestic patients carry out "cross-border diagnosis and treatment".
This is a new blue ocean market, but in March 20 18, Ke Ranhong, the legal representative of pharmaceutical sales, and others were criminally detained by Shangcheng Branch of Hangzhou Public Security Bureau on suspicion of selling counterfeit drugs. Due to lactation, the compulsory measure for Ke Ranhong was changed to bail pending trial.
The prosecution has filed a public prosecution on 20 19 10 16, and the trial has not yet started.
From the beginning, this change can be traced back to the "Zhen 'an Incident" three years ago.
The "Zhen 'an Incident" was a man-made disaster. From 2065438 to February 2006, some hemodialysis patients were found to be positive for HCV antibody in Zhen 'an County Hospital, Shangluo City, Shaanxi Province. According to the conclusion of the investigation team, there were 26 patients infected with hepatitis C virus, and "the cause of the accident was illegal operation".
China is a low-prevalence area of hepatitis C, and the main route of transmission is blood transmission. It is generally believed that "hepatitis B" is a major health hazard lurking in the population, but in fact, hepatitis C is an important cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. "It only takes one year for hepatitis C to evolve into cirrhosis and hepatocellular carcinoma," said Ke Ranhong.
In the follow-up treatment, some patients contacted the doctor to enjoy the sale by calling customer service. Ke Ranhong recalled that at that time, the official adopted the traditional treatment plan-interferon combined with ribavirin. After the start of treatment, most patients showed symptoms of drug intolerance, and some patients showed virus rebound during treatment, "basically failed."
In fact, patients with "hepatitis C" had a more useful treatment plan at that time: the combination of sofebuvir and dakatavir. In 20 13, sofebuvir, the original drug used by American pharmaceutical company Gilead to treat chronic hepatitis C, was approved for marketing in the United States. The following year, Bristol-Myers Squibb, another American pharmaceutical company, was allowed to conduct original research on dacitavir, a hepatitis C drug.
The combination of these two drugs can completely eliminate various genotypes of hepatitis C virus. However, this program needs three months as a course of treatment. At that time, Sofebuvir needed $90,000 and Dhaka Tavil needed $84,000, which was tantamount to an "astronomical figure" for most people.
The patients in the "Zhen 'an Incident" went to doctors to enjoy sales because they got cheap generic drugs through this company.
Ke Ranhong is also embarrassed. She initially thought of an optimal plan to send these patients directly to hospitals in the United States or Japan for treatment. However, patients can't pay high treatment costs, and the official budget is very limited. "Only 30,000 to 40,000 yuan" is far from enough.
Due to the poor physical condition and limited funds, the doctor finally decided to contact Laos Friendship Hospital to provide remote diagnosis and treatment. This has become the foreshadowing of disputes involving medical enjoyment and sale.
Laos has been able to legally produce and use two hepatitis C generic drugs on 20 15. In China, the original American drugs such as sofebuvir and danavir were not approved for marketing until 20 17.
Before taking over the "Zhen' an patients", medical enjoyment sales provided a mode of going abroad for medical treatment. The company docked the patient with the hospital, and the patient went to Laos Friendship Hospital for treatment and returned to China after taking the medicine. In this process, medical sharing provides services such as resource docking and collects service fees. Together with the diagnosis and drug costs, the patient's expenditure "will not exceed 6.5438+10,000 yuan".
"Zhen' an patients" cannot apply the mode of going abroad for medical treatment. Wang Cheng recalled that the company also thought about whether to intervene in this incident, about three months or so, and finally decided to intervene.
Moreover, Ke Ranhong thinks he is sure. "Zhenan patients" were divided into three groups. The first group consists of three or four people who have mild symptoms and are basically healthy, and their hepatitis C virus has been completely eliminated. For the second batch of more serious patients, medical experts from the United States and Japan were consulted and their suggestions and treatment plans were consulted. In the end, all three groups of patients who enjoyed medical services cured hepatitis C.
Recalling the "Zhen 'an Incident" again, Ke Ranhong does not deny his emotionalization. She said that her friends also thought she was an emotional person.
Ke Ranhong was born in 1975. There are elders in his family who are engaged in the medical industry. Graduated from Zhejiang University of Traditional Chinese Medicine, majoring in integrated traditional Chinese and western medicine. Although the positions I have held are very miscellaneous, they are all related to the pharmaceutical industry. She said that as early as around 2000, she envisioned introducing foreign drugs into China.
The logic is simple. Since there is a new and more effective treatment plan, "why use the old one?" Ke Yuhong said.
However, contrary to expectations, the domestic examination and approval procedures for imported drugs are extremely long. She didn't intend to give up, but was inspired to register and set up medical sales on 20 15. The start-up capital of this venture comes from the income after she sold two suites under her name. "One set in Hangzhou and one set in Shanghai sold 6 million together."
Only at that time, the institutional dilemma of drug introduction had not disappeared. Ke Ranhong introduced that to introduce a new drug, it is necessary to pay three or four times only to declare the information and queue for at least three years. It will take a long time to enter the clinical safety and effectiveness research after the project is assigned to China laboratory for testing. By 20 18, the drug introduction system has been improved.
Keranhong smiled rather helplessly. She said that if you start a business on 20 18, it will definitely be much smoother.
Pharmaceutical sales have never been profitable, but when its business began to improve, it suffered a "disaster".
After the Zhen 'an incident, the feasibility of remote diagnosis and treatment was tested by selling medical services, and the "Hepatitis C Project" changed from the mode of going abroad for medical treatment to the mode of remote diagnosis and treatment. Ke Ranhong introduced that "Hepatitis C Project" is one of the company's main businesses, and its profit accounts for 45% of the company's total income.
Comparatively speaking, among medical companies, the more profitable projects are to provide overseas physical examination, genetic testing, cancer treatment and other services. Although the hepatitis C project has many customers, its profit rate is low.
Under the mode of going abroad for medical treatment, the medical enjoyment fee is 30 thousand yuan. Among them, 20,000 yuan was given to Yongzhen Wan Tai, and 1 10,000 yuan was taken by himself.
Under the remote diagnosis and treatment mode, the medical fee is 6000 yuan, "most customers charge between 2500-3500 yuan".
The full name of "Yongzhen Wan Tai" is Hangzhou Yongzhen Wan Tai Health Consulting Co., Ltd., which is a medical sales partner. Ke Ranhong introduced that she met Fan Wenjun, the head of Yongzhen Wan Tai, through an old friend of 10. Fan Wenjun has lived in Laos for nearly 10 years and has certain contacts. The aforementioned cooperative relationship with Laos Friendship Hospital was also reached with the support of Fan Wenjun and others.
Ke Ranhong recalled that at the beginning, Medical Enjoy Sales and Yongzhen Wan Tai originally signed a contract with the hospital to represent hepatitis C projects in various regions of China, which was a "parallel structure". But later, Yongzhen Wan Tai gradually became keen to directly participate in the promotion and docking of hepatitis C projects, and medical sharing sales actually became its "subcontractor".
Yongzhen Wan Tai took the lead in the accident.
According to the indictment of Fan Wenjun's case, on February 26th, 20 17 17, Han, an employee of Fan Wenjun Company, was seized by Guangzhou Customs while bringing a batch of generic drugs into the country. The public security organs also seized naked drugs, raw materials and packaging materials with a value of140,000 yuan in the warehouse of Fan Wenjun Company, involving more than 40 generic drugs that have not obtained the drug import approval number.
The fire soon spread to the medicine store.
On 20 18 1.20, the pharmaceutical sales company was investigated. Subsequently, Ke Ranhong, the legal representative of the company, Chen Mou, the account manager, and three medical representatives in Hangzhou were detained in criminal detention. Because of breastfeeding, Ke Ranhong was released on bail on the same day.
In fact, on March 9, 2008+2065438, Ke Ranhong, who had just given birth to a child for two months, returned to China and took the initiative to go to the police station for investigation. She repeatedly stressed: "I am involved with the pharmaceutical sales company."
According to the indictment, the People's Procuratorate of Shangcheng District accused Ke Ranhong and Fan Wenjun of assisting Yongzhen Wan Tai to sell drugs such as sofebuvir and dacitavir, which were produced in Laos and imported without approval. By the time of the crime, the profit was RMB 7,665,438+0,000.
According to the indictment, from the end of 20 15, Medical Enjoy Marketing launched "telemedicine", and the drug purchase fee was paid directly by the patient to the overseas account controlled by Yongzhen Wan Tai Company, or to the corporate account of Medical Enjoy Marketing Company and the personal account of "Tang Zhongying", and then transferred to Yongzhen Wan Tai. Pharmaceutical sales companies get drug sales rebates from it.
Sun Haiyang, the defense lawyer of Ke Ranhong and lawyer of Tianchi Juntai Law Firm, believes that Ke Ranhong does not constitute a crime. She said that Ke Ranhong and the pharmaceutical sales company don't sell medicines. All they do is help patients cross the border for medical treatment. The fees charged are consulting service fee and follow-up service fee.
At present, the Fan Wenjun case has not been pronounced after the trial, and the Ke Ranhong case has not yet been heard.
Ke Ranhong said that he didn't know about the cross-border drug-carrying behavior of Yongzhen Wan Tai personnel before, and "Medical Enjoy Sales insisted on assisting customers to seek medical treatment".
According to Wang Cheng, after the patients served by the pharmaceutical sales center are diagnosed in domestic hospitals, they submit relevant certificates and cases to the pharmaceutical sales center, and then the doctors in Laos prescribe them and send the drugs to the patients through EMS. "It will never pass through our own hands."
In the understanding of Ke Ranhong and Wang Cheng, this is called "personal drug abuse", which is a special case not stipulated in the Drug Administration Law and does not constitute a crime. Medical personnel who provide services cannot be punished as crimes.
Medical sales claim that Wan Tai's cross-border drug abuse behavior is unknown. "It depends on the evidence. If you really don't know, the court should consider it when sentencing, "Li Sheng said.
After the release of "Die to Live" in August 20 18, some people compared Ke Ranhong to a "drug god" to correspond to what happened three years ago. Ke Ranhong said with a smile: "I am really not a drug god. The drug god in the movie did bring drugs across the border, but I don't have them here. "
However, the influence of movies is still great. Some judicial personnel she came into contact with will also talk to her about this film and comment that it is very similar to her. Ke Ranhong made a joke. She asked the judicial personnel: "Then you know that the prototype of the drug god in reality has not been prosecuted?"
"Really?" The judicial officers she questioned were all shocked.
"yes." Ke Yuhong said.
Editor | zy@nfcmag.com, Zhao Yi
Typesetting | Intimate Intern Xu Yuejiao
The window of the south is produced by new media.